Scott Peters
19 Apr, 2022
New York City
Johnson & Johnson said first-quarter 2022 revenues increased 5% to $23.4 billion, net income declined 17% to $5.14 billion, and earnings per share by the same amount to $1.93 from $2.32 a share a year ago. Sales in the U.S. rose 2.7% to $11.4 billion and international sales jumped 7.2% to $12 billion. The pharmaceutical maker guided full-year 2022 revenue growth in the range between 3.8% to 4.8% from the previous guidance range between 5% to 6% and also suspended its guidance on Covid-19 vaccine sales.
